(R)-Thalidomide is a COX 1/2 inhibitor that induces apoptosis in MCF-7, IM-9, HS-Sultan, KB and other cancer cells.

With the affinity of (R)-Thalidomide by the MIP present surface capture, that is more strongly than the other forms. In the case of (R)-Thalidomide, it is found to bind to the selective sites of the MIP more strongly than the other which reflects their different biological entities[1]. The (S)-Thalidomide imprints MIP nanoparticles exerted a greater cytotoxic effect on the caco-2 cells than the (R)-Thalidomide imprinted MIPs[1].

方法：成年雌性 F344 大鼠颅内、皮下 （侧腹） 或两者植入 9L 胶质肉瘤肿瘤。治疗数周后评估单独口服沙利度胺以及与腹膜内 BCNU 或顺铂联合化疗的有效性。通过手性 HPLC 测定治疗后收集的假定假稳态血清、肿瘤和其他组织 S-和 (R)-Thalidomide 。
结果：(R)-Thalidomide 的血清和组织浓度均比 (S)-Thalidomide 高 40-50%。[1]